Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

Accordingly, investing in AI-driven precision oncology companies presents a compelling long-term opportunity for investors. BioXcel: The company expedites the discovery and development of new ...

Introduction Oncology drugs are medications used to prevent or treat cancer. These include chemotherapy, targeted therapy, immunotherapy, and h ...

While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are in spotlight as of now. The Zacks ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Companies remain exposed to heightened risks between the world’s largest markets and are cautious of the stability of ...

Almost six years on, we're one of the fastest growing oncology companies in the world. We continue to drive forward with this approach supporting patients with cancer in the UK, and around the world.